Literature DB >> 1336666

Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene.

H Tsuda1, S Satarug, V Bhudhisawasdi, T Kihana, T Sugimura, S Hirohashi.   

Abstract

Point-mutational activation of the c-Ki-ras proto-oncogene has been shown to be rare in human hepatocellular carcinoma, the most common primary liver cancer and one usually associated with chronic viral infection. To reveal the association of c-Ki-ras activation with cholangiocarcinogenesis under different etiological backgrounds, the incidence of point mutation at codons 12 and 13 of the c-Ki-ras proto-oncogene was examined in three groups of human liver cancers with differentiation to biliary epithelial cells: Group 1, cholangiocellular carcinoma in Japanese with normal livers; Group 2, cholangiocellular carcinoma in Thais who had lived in an area where the liver fluke Opisthorchis viverrini is endemic; and Group 3, combined hepatocellular-cholangiocellular carcinoma, a rare type showing features of both hepatocellular and biliary epithelial differentiation, in Japanese with chronic viral hepatitis with or without cirrhosis. The polymerase chain reaction and direct sequencing of its product were used to detect the mutation. Point mutation at codon 12 of the c-Ki-ras gene was detected in five (56%) of nine cases in Group 1. In contrast, the mutation was not detected in any of the cases in Groups 2 and 3. Therefore, point-mutational activation of c-Ki-ras did not seem to be involved in the development of primary liver cancers associated with apparent chronic irritation of liver cells or biliary epithelial cells caused by exogenous liver-fluke or viral infection. On the other hand, point-mutational activation of the c-Ki-ras proto-oncogene may be involved in cholangiocarcinogenesis in liver without preexisting liver-fluke or viral infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336666     DOI: 10.1002/mc.2940060408

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  7 in total

1.  Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples.

Authors:  A Khalid; R Pal; E Sasatomi; P Swalsky; A Slivka; D Whitcomb; S Finkelstein
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

2.  Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

Authors:  Ymera Pignochino; Ivana Sarotto; Caterina Peraldo-Neia; Junia Y Penachioni; Giuliana Cavalloni; Giorgia Migliardi; Laura Casorzo; Giovanna Chiorino; Mauro Risio; Alberto Bardelli; Massimo Aglietta; Francesco Leone
Journal:  BMC Cancer       Date:  2010-11-18       Impact factor: 4.430

Review 3.  An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.

Authors:  Pattaya Seeree; Phorutai Pearngam; Supeecha Kumkate; Tavan Janvilisri
Journal:  Int J Genomics       Date:  2015-09-02       Impact factor: 2.326

4.  Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas.

Authors:  Y Imai; H Oda; M Arai; S Shimizu; Y Nakatsuru; T Inoue; T Ishikawa
Journal:  Jpn J Cancer Res       Date:  1996-10

5.  A diagnostic challenge presented in a 37-year-old man with severe weight loss and multiple liver masses.

Authors:  Saeed Abdi; Amin Momeni Moghadam; Mitra Rafiezadeh; Forough Mangeli; Ayub Ghafurian
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

6.  Ki-ras point mutations and proliferation activity in biliary tract carcinomas.

Authors:  K Ohashi; M Tstsumi; Y Nakajima; H Nakano; Y Konishi
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

7.  Association of Fasciola hepatica Infection with Liver Fibrosis, Cirrhosis, and Cancer: A Systematic Review.

Authors:  Claudia Machicado; Jorge D Machicado; Vicente Maco; Angelica Terashima; Luis A Marcos
Journal:  PLoS Negl Trop Dis       Date:  2016-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.